Effect of Morin on Pharmacokinetics of Prasugrel in Rats & In Vitro Metabolic Stability Followed by UPLC Method

Kapendra Sahu1,2* and Anees A. Siddiqui1*

1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi (India)-110062.
2National Dope Testing Laboratory, MYAS, Government of India, Lodhi Road, New Delhi (India) -110003

*Corresponding authors: Kapendra Sahu., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi (India)-110062, Tel: +91-11-26059688/5650; Fax: +91-11 27048685; E-mail: kapendra_sahu@yahoo.com

Abstract

The aim of present study was to investigate the effect of Morin on the pharmacokinetics of Prasugrel, a substrate of P-glycoprotein (P-gp) and Cytochrome 3A (CYP3A), in rats, and metabolic stability (high throughput) studies using human liver microsomes in UPLC. For pharmacokinetics studies, Male wistar rats were pretreated with Morin (10 mg/kg) for 1 week and on the last day, a single dose of Prasugrel (1 mg/kg) was given orally. In another group, both morin and Prasugrel were co-administered to evaluate the acute effect of morin on Prasugrel. The control group received oral distilled water for 1 week and administered with Prasugrel on the last day. As Morin is a known inhibitor of P-Glycoprotein (P-gp) and CYP 3A, it was expected to improve the bioavailability of Prasugrel. Surprisingly, the area under the concentration–time curve and peak plasma concentration relative to control of Prasugrel were 1.50- and 1.45-fold, respectively, greater in the morin-pretreated group. However, co-administration of morin had no significant effect on these parameters. Prasugrel dosages should be accustomed to avoid concomitant for potential drug interaction when Prasugrel is used clinically in combination with morin and morin-containing dietary supplements. Apart from aforementioned merits, the results of this study are further confirmed by clinical trials.

Keywords: Prasugrel; Human Liver Microsomes; Pharmacokinetics; CYP3A; in vivo; in vitro; UPLC.

Introduction

Prasugrel is a prodrug of piperazine derivative (Figure 1) that inhibits platelet aggregation in vivo by antagonism of the P2Y12 class of platelet purinergic receptors[1-3]. Subsequent studies showed that the conversion of active metabolite is mediated largely by Cytochrome (CYP) 3A4 and CYP2B6 and, to a lesser extent, by CYP2C9 and CYP2C19[4,5].

Figure 1: Chemical structure of Prasugrel.

Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one) is a flavonoid (flavonol) constituent of many herbs and fruits. In vitro studies have shown morin to have a variety of beneficial activities, including anti-cancer, antioxidant, anti-inflammation etc[6,7]. Now a day in vitro metabolic stability is incorporated into the drug discovery process. These studies facilitate analytical approach comprised specificity and higher throughput. By understanding the metabolic stability of compounds early in discovery, compounds can be ranked for further studies and the potential for a drug candidate to fail in development as a result of pharmacokinetic reasons may be reduced[7]. The full Pharmacokinetics (PK) studies, rapid screens offer significant savings in the in-life portion by standardizing dosing and study protocols, eliminating study arms, reducing animal usage and limiting the number of sampling points[8,9]. Buening.,

Received Date: March 23, 2017
Accepted Date: April 25, 2017
Published Date: May 02, 2017


Keywords: Prasugrel; Human Liver Microsomes; Pharmacokinetics; CYP3A; in vivo; in vitro; UPLC.

DOI: 10.15436/2575-808X.17.1439

CrossMark

Copyrights: © 2017 Sahu, K. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
et al. also reported that morin could inhibit cytochrome P-450 reductase in human liver microsomes. Orally administered morin, act as P-gp and CYP3A inhibitors, may provide inhibition of platelets aggregation effects to ameliorate the bioavailability of Prasugrel in combination therapy. Therefore, the purpose of this study examined the effect of morin on the bioavailability and pharmacokinetics of Prasugrel in rats. So far to our knowledge there was no method has been reported for UPLC method yet on the method development, effect of morin on pharmacokinetics of Prasugrel, and in vitro metabolic stability studies for this drug.

Experimental

Chemicals
Prasugrel and clopidogrel were obtained as a gratis sample from Micro Labs. Limited (Bangalore, India). Morin, Midozolam and 6-Hydroxy Midozolam were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). HPLC grade methanol and acetonitrile were obtained from Merck Co. (Darmstadt, Germany). Pooled human liver microsomes from 30 donors were purchased from BD Gentest (Woburn, MA). Ammonium acetate, magnesium chloride and ethyl acetate were all obtained from Merck (Germany). NADPH reduced tetrasodium salt was purchased from Sisco Research Laboratories, (Mumbai, India). Potassium dihydrogen ortho-phosphate, orthophosphoric acid and potassium hydroxide were purchased from Sigma Aldrich Ltd (St Louis, USA). Milli-Q pure water was obtained from Millipore Elix water purification system purchased from Millipore India Pvt. Ltd. (New Delhi, India). All other chemicals were of analytical grade.

Animals and legal prerequisite
Young, adult male Wistar rats, weighing 200 - 230g, were procured from the Institutional Animal Ethics Committee (IAEC), Jamia Hamdard (New Delhi, India). Rats were housed in well ventilated cages at room temperature (24 ± 2°C) and 40-60 % relative humidity while on a regular 12 h light-dark cycle. The animals were acclimatized for a minimum period of 3 days prior to the experiment. Approval from the Committee was sought and the study protocols were approved before the commencement of the studies.

Instrumentation

Ultra Performance Liquid Chromatography (UPLC)
UPLC was performed with a binary solvent delivery pump, an auto sampler and PDA detector of Acquity UPLC system manufactured by Waters Corporation; Milford, Massachussets, USA; data were acquired and processed using Empower software. The chromatographic separation was performed using a Waters Acquity BEH 10 × 2.1 mm, 1.7 μm, C18 column.

UPLC conditions for plasma sample analysis
Prasugrel was estimated in plasma samples using UPLC method. The chromatographic separation was performed using a Waters Acquity BEH 10 × 2.1 mm, 1.7μm, C18 column. The mobile phase containing a mixture of acetonitrile and water in the ratio of 30:70 (v/v) at a flow rate of 0.2 mL/min was used. The detection was obtained at a wavelength of 240 nm. The injection volume was 3 μL; mobile phase was used as a diluent while the column was maintained at 30°C. These studies were carried out using a photo diode array detector for checking purity of peaks.

Pharmacokinetics of morin
Wistar Rats were divided into three groups of each of five: the control group (Prasugrel 30 mg/kg, oral), co-administration group (10 mg/kg of morin orally co-administered with 30 mg/kg of Prasugrel) and pretreatment group (1 mg/kg of Prasugrel was administered orally after 1-week pretreatment with morin 10 mg/kg). Blood samples (approx. 150 μl) from retro-orbital plexus were collected into heparinized microfuge tubes at 0.5, 1, 1.5, 2, 4, 8, 12, and 24 h post-dosing and plasma was harvested by centrifuging the blood at 14,000 rpm for 10 min and stored frozen at -20°C until bioanalysis.

Preparation of stock and standard solutions
The primary stock solutions of the analyte (Prasugrel; 5mg/mL) and IS (Clopidogrel); 200 μg/mL) were prepared in water and stored at 4°C. Appropriate dilutions were made in water for Prasugrel to produce working stock solution of 0.01, 0.02, 0.1, 0.5, 1 & 2 mg/mL and on the day of analysis this set of stocks was used to prepare standards for the calibration curve. Another set of working stock solutions of Prasugrel was made in Triple Distilled Water (TDW) at 0.2, 2, and 15 μg/mL for preparation of QC samples. Individually QC and CC working stock solutions of Prasugrel were spiked into blank plasma for QC and CC samples. Calibration plots were constructed in the range 0.1 – 20 μg/mL for Prasugrel in rat plasma (concentrations 0.1, 0.2, 1, 5, 10 and 20 μg/mL). Calibration standards were prepared by spiking 90 μL of control pooled rat plasma with the appropriate working solution of Prasugrel (10 μL) and IS (10 μL) on the day of analysis. Samples for the determination of precision and accuracy were prepared by spiking control rat plasma in bulk at four concentration levels [40 ng/mL (lower limit of quantitation, LLOQ), 0.2 μg/mL (QC low), 2 μg/mL (QC medium) and 15 μg/mL (QC high)] and 100 L volumes were aliquoted into different tubes and stored at -20°C until analysis.

Sample preparation
A simple liquid–liquid extraction method was followed for extraction of Prasugrel from rat plasma. To 100 μL of plasma in a tube, 10 μL of IS solution (200 μg/mL in water), vortex mixed for 30 seconds on a cyclomixer (Spinix Tarsons, Kolkatta, India). Next a 3 mL aliquot of extraction solvent, butanol was added. The mixture was then vortexed for 5 min, followed by centrifugation for 5 min at 3000×g at 25°C on Sigma 3 - 16K (Frankfurt, Germany). The organic layer of 2 ml was separated and evaporated to dryness under vacuum in speedvac concentrator (Savant Instrument, Farmingdale, USA). The residue was reconstituted in 100 μL of the mobile phase and 3 μL was injected into the UPLC system for analysis.

Validation Procedures
A full validation according to the FDA guidelines was performed for the assay in rat plasma.

Recovery
The recovery of Prasugrel and IS, through liquid–liquid extraction procedure, was determined by comparing the responses of the analytes extracted from replicate QC samples (n
Effect of Morin on Pharmacokinetics of Prasugrel

The range of a correlation coefficient (r) for Prasugrel was strictly linear in the investigated concentration curve were 0.1, 0.2, 1, 2, 5, 10 & 20 µg/mL. The response for the concentration of calibration standards. The final concentrations of the peak area of Prasugrel to that of IS versus the nominal value was determined at a single concentration of 2 µg/mL.

**Calibration Curve**

The calibration curve was developed by plotting the ratio of the peak area of Prasugrel to that of IS versus the nominal concentration. The concentration of 200 ng/mL.

**Precision and Accuracy**

The intra-day assay precision and accuracy were estimated by analyzing six replicates at four different QC levels, i.e., 0.2, 2 and 15 µg/mL. The response for Prasugrel was strictly linear in the investigated concentration range of a correlation coefficient ($r^2$) of 0.9995. The acceptance criteria for each back-calculated standard were ±15% deviation from the nominal value except at LLOQ, which was set at ±20% [10, 11].

**Stability Experiments**

All stability studies were conducted at two concentration levels, i.e. QC low and QC high, using six replicates at each concentration level. Replicate injections of processed samples were analyzed up to 18 h to establish auto-sampler stability of analyte and IS at 4°C. The peak areas of analyte and IS obtained at initial cycle were used as the reference to determine the stability at subsequent points.

The stability of Prasugrel in the biomatrix during 4 h exposure at room temperature in rat plasma (bench top) was determined at ambient temperature (25 ± 2°C). Freeze/thaw stability was evaluated up to three cycles. In each cycle samples were frozen for at least 12 h at −80 ± 10°C. Freeze stability of Prasugrel in rat plasma was assessed by analyzing the QC samples stored at −80 ± 10°C for at least 15 days. Samples were considered to be stable if assay values were within the acceptable limits of accuracy (i.e., ±15% S.D.) and precision (i.e., ±15% R.S.D.)

**Application to a pharmacokinetic study in rats**

*In vivo* oral pharmacokinetic study was performed in male wistar rats (n = 5, weight range 200 – 220 g) to demonstrate the applicability of newly developed and validated bioanalytical method using UPLC. Prasugrel was administered orally at a dose of 30 mg/kg in 0.25% sodium Carboxy Methyl Cellulose (CMC) suspension. Blood samples were collected from the retro-orbital plexus of rats under light ether anesthesia into microfuge tubes containing heparin as an anti-coagulant at 0.5, 1, 2, 3, 4, 5, 8, 10, 12 and 24 h post-dosing. Plasma was harvested by centrifuging the blood at 2500×g for 5 min at 20°C and stored frozen at −80 ± 10°C until analysis. Rat plasma (100 µL) samples were spiked with IS and processed as described above and data was accepted based on the performance of QC samples prepared using rat blank plasma (four QCs each at three concentration levels). The criteria for acceptance of the analytical runs encompassed the following: (i) not more than 33% of the QC samples were greater than ±15% of the nominal concentration; (ii) not less than 50% at each QC concentration level must meet the acceptance criteria. Plasma concentration-time data of Prasugrel was analyzed by non-compartmental method using WinNonlin Version 5.1 (Pharsight Corporation, Mountain View, USA).

**Statistical analysis**

Statistical analysis was performed by one-way ANOVA followed by Tukey’s test using Graph Pad prism software. All experimental values are expressed as mean ± Standard Deviation (SD). A value of $P < 0.05$ was considered significant. The pharmacokinetics parameters were determined non-compartmental method using WinNonlin Version 5.1 (Pharsight Corporation, Mountain View, USA).
Results & Discussion

Development and Optimization of the UPLC Method

Primarily, the drug was analyzed on a BEH C8 column using acetonitrile: water (50:50) as mobile phase at a flow rate of 0.15 mL/min. and a column temperature of 25°C. Under these conditions, the shape of the drug peak was not acceptable. Subsequent trials were made on plasma samples using different amounts of acetonitrile, pH and temperature. The peaks for this drug and the degradation products were not well separated or did not have an acceptable shape at column temperatures < 30°C and acidic pH. The best separation was achieved on the same column at 30°C using the mobile phase acetonitrile: water (25:75) in an isocratic mode. The flow rate was kept at 0.3 mL/min at constant volume 3 μL and the detection wavelength was 240 nm.

Validation procedures of developed method

Recovery

The results of the comparison of pre-extracted standards versus post-extracted plasma standards were estimated for Prasugrel at 0.2, 2 and 15 µg/mL and the absolute percent mean recovery for Prasugrel at 0.2, 2 and 15 µg/mL were found to be 95.00%, 101.55% & 97.65% respectively. The absolute recovery of IS at 2 µg/mL was 90.35%.

Matrix effect, specificity and selectivity

In this study, the matrix effect was evaluated by analyzing QC low (0.2 µg/mL), QC medium (2.0 µg/mL) and QC high samples (15 µg/mL). Average matrix effect values obtained were 10.8, 12.8 and 8.8% at QC low, QC medium and QC high, respectively. Matrix effect on IS was found to be 4.6% at tested concentration of 2 µg/mL.

The specificity and selectivity has been studied by using independent plasma samples from six different rats. The specificity and selectivity has been studied by

Recovery

The results of the comparison of pre-extracted standards versus post-extracted plasma standards were estimated for Prasugrel at 0.2, 2 and 15 µg/mL and the absolute percent mean recovery for Prasugrel at 0.2, 2 and 15 µg/mL were found to be 95.00%, 101.55% & 97.65% respectively. The absolute recovery of IS at 2 µg/mL was 90.35%.

Precision and Accuracy

The precision of the method was determined by calculating RSD for QCs at three concentration levels over three validation days. The Intra-day and inter-day precision was found to be range of 0.87 - 3.52 and 1.13 - 8.50 respectively at all QC levels (0.2, 2, and 15 mg/mL). The accuracy of the method ranged from 90.33 to 101.54% at each QC level. Assay performance data are presented in Table 2. The above results demonstrate that the values are within the acceptable range and the method is accurate and precise.

Table 2: Precision and accuracy for Prasugrel of quality control sample in rat plasma (n = 5).

<table>
<thead>
<tr>
<th>Nominal Concentration (µg/mL)</th>
<th>Observed Concentration Mean ± SD</th>
<th>Precision (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2</td>
<td>0.190 ± 0.002</td>
<td>0.991</td>
<td>95.167</td>
</tr>
<tr>
<td>2</td>
<td>2.031 ± 0.072</td>
<td>3.526</td>
<td>101.533</td>
</tr>
<tr>
<td>15</td>
<td>14.648 ± 0.128</td>
<td>0.872</td>
<td>97.665</td>
</tr>
<tr>
<td>0.2</td>
<td>0.181 ± 0.015</td>
<td>8.507</td>
<td>90.333</td>
</tr>
<tr>
<td>2</td>
<td>2.031 ± 0.144</td>
<td>7.090</td>
<td>101.543</td>
</tr>
<tr>
<td>15</td>
<td>14.648 ± 0.167</td>
<td>1.138</td>
<td>97.656</td>
</tr>
</tbody>
</table>

*Expressed as % R.S.D. = (S.D/mean) x 100.

Table 3: Summary of stability of Prasugrel under various storage conditions (n = 5).

<table>
<thead>
<tr>
<th>Condition</th>
<th>Spiked concentration</th>
<th>found concentration</th>
<th>RSD (%)</th>
<th>RE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambient, 2 h</td>
<td>0.2</td>
<td>0.184</td>
<td>15</td>
<td>6.530</td>
</tr>
<tr>
<td>-20°C, 30 days</td>
<td>0.2</td>
<td>0.190</td>
<td>15</td>
<td>10.500</td>
</tr>
<tr>
<td>Three freeze–thaw</td>
<td>0.2</td>
<td>0.198</td>
<td>15</td>
<td>12.392</td>
</tr>
<tr>
<td>Autosampler ambient 24 h</td>
<td>0.2</td>
<td>0.182</td>
<td>15</td>
<td>8.594</td>
</tr>
<tr>
<td>10 days -80°C</td>
<td>0.2</td>
<td>0.186</td>
<td>15</td>
<td>9.614</td>
</tr>
</tbody>
</table>

RE % = (observed-nominal)/nominal X 100

Stability

The stability results showed that Prasugrel spiked into rat plasma was stable for 2 h at room temperature, for 30 days at -20°C, and during three freeze–thaw cycles. Stability of Prasugrel extracts in the sample solvent on an auto sampler was also observed over a 24 h period. The long-term stability was assessed after storage of the standard spiked plasma samples at -20°C for 30 days. The results of stability experiments are listed in Table 3.

Table 1: Retention times and relative retention times of various peaks with their peak purity data.

<table>
<thead>
<tr>
<th>PEAKS</th>
<th>UPLC</th>
<th>Retention Time (Rt)</th>
<th>Relative Retention Time (RRr)</th>
<th>Peak purity angle</th>
<th>Peak threshold</th>
<th>Resolution factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prasugrel</td>
<td>0.61</td>
<td>1</td>
<td>2.9</td>
<td>4.1</td>
<td>3.1</td>
<td></td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>0.41</td>
<td>0.67</td>
<td>2.2</td>
<td>3.3</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Morin</td>
<td>1.5</td>
<td>2.45</td>
<td>2.9</td>
<td>3.5</td>
<td>3.5</td>
<td></td>
</tr>
</tbody>
</table>

Rt = Retention time (minutes)
RRr = Relative retention time

Calibration curve and sensitivity

The linear regressions of the peak area ratios versus concentrations were fitted over the concentration range 0.1–20 µg/mL for Prasugrel in rat plasma. A typical equation of the calibration curve was: y = 0.0754x + 0.0021, r² = 0.9977, where y represents the ratios of Prasugrel peak area to that of IS and x represents the plasma concentration. The LLOQ for the determination of Prasugrel in plasma was 0.1 µg/mL. The precision and accuracy at LLOQ were 9.2 and 90.2% respectively.
Pharmacokinetics studies

The pharmacokinetic results are shown in Figure 2 and its parameters are summarized in Table 4. The statistical comparison of mean plasma concentration of Prasugrel in three groups by one-way ANOVA followed by Tukey’s test revealed significantly higher (P < 0.01) plasma. The level of prasugrel from 2 to 24 h in morin-pretreated group in comparison with the control and morin co-administered groups. However, no significant change (P > 0.05) was observed in plasma concentration of Prasugrel in morin co-administered group at all the studied time points in comparison with that of control group. Further, analysis of pharmacokinetic parameters revealed that morin pre-treatment caused a significant elevation in C_{max} (1.4 fold) of Prasugrel in comparison with the control group and co-administered groups at 0.5 hr as shown in Figure 2. As the results shown in Table 4, the elimination half-life (t_{1/2}), AUC_{0-t}, Clearance (CL), Mean Residential Time (MRT) also affected with respect to time in comparison at different groups (control, co-administered & pre-treated).

![Figure 2: Mean plasma concentration–time profiles after the oral administration of prasugrel (control, 30 mg/kg), co-administration (prasugrel + morin) & pre-treatment Bars represent the standard deviation (n = 5).](image)

![Table 4: Pharmacokinetic parameters after oral administration of single dosage 30 mg/kg Prasugrel to rats (n = 6).](table)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control Mean ± SD</th>
<th>Morin (co-administered) + PCM</th>
<th>Morin (pretreatment) + PCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean of observed concentration N = 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{max} (µg/ml)</td>
<td>16.112</td>
<td>16.218</td>
<td>18.994</td>
</tr>
<tr>
<td>T_{max} (h)</td>
<td>0.500</td>
<td>0.500</td>
<td>0.500</td>
</tr>
<tr>
<td>AUC_{0-t} (µg h/ml)</td>
<td>95.104</td>
<td>97.115</td>
<td>125.221</td>
</tr>
<tr>
<td>AUC_{0-∞} (µg h/ml)</td>
<td>97.001</td>
<td>98.211</td>
<td>130.567</td>
</tr>
<tr>
<td>CL (L/h/kg)</td>
<td>00.621</td>
<td>00.658</td>
<td>00.455</td>
</tr>
<tr>
<td>t_{1/2} (h)</td>
<td>07.574</td>
<td>07.998</td>
<td>09.862</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>06.112</td>
<td>06.554</td>
<td>07.236</td>
</tr>
<tr>
<td>% RB</td>
<td>100</td>
<td>101.24</td>
<td>134.60</td>
</tr>
</tbody>
</table>

Relative bioavailability (RB) % = AUC co-admin or pre-treated/ AUC control × 100.

In vitro metabolic stability

Metabolic stability has been defined as the percentage of parent compound lost over time in the presence of the test system. Because a majority of drug metabolism occurs in the liver, the in vitro human liver microsomes have been used to evaluate metabolic stability. By understanding the metabolic stability of compounds early in discovery, the potential for a drug candidate to fail in development as a result of pharmacokinetic reasons may be reduced. Microsomes may be more applicable because of the low volumes used in these assays and to achieve goal is to screen Prasugrel in a high-throughput manner. The metabolic stability of Prasugrel is determined using human liver Microsomes in an in vitro design. Approximately, 65% of the intact Prasugrel remained in the incubation mixture over the time of 120 minutes as shown in Figure 3. This indicates that the drug Prasugrel was significant metabolize and instable in human liver Microsomes up to 2 hrs at 37 ± 1°C with half life of 78.31 hr. The non-linear regression analysis of the data showed good fitting with mono exponential decay followed by degree of freedom of 18 were calculated by graph pad prism software. The determined parameters are rate constant (K min^{-1}), half life (t_{1/2} mins), Degree of Freedom (df) & regression co-efficient (r^2) shown in Table 5.

![Figure 3: Plot of parent drug remaining in the incubation mixture versus time of prasugrel.](image)

![Table 5: Metabolic stability data for Prasugrel.](table)

<table>
<thead>
<tr>
<th>parameters</th>
<th>Observed values</th>
</tr>
</thead>
<tbody>
<tr>
<td>K (min^{-1})</td>
<td>0.0088</td>
</tr>
<tr>
<td>t_{1/2} (minutes)</td>
<td>78.31</td>
</tr>
<tr>
<td>R^2</td>
<td>0.995</td>
</tr>
<tr>
<td>Df (degree of freedom)</td>
<td>18</td>
</tr>
</tbody>
</table>

Conclusion

The method proved to be simple, accurate, faster, precise, specific and selective. Further, the present study suggests that there might be a potential interaction between Prasugrel and Morin and therefore, quantitative evaluation of Prasugrel–morin interaction in humans needs to be verified to avoid food–drug interactions. The pre-treatment of naturally occurring dietary supplement morin significantly increased the relative bioavailability of prasugrel. It is hoped that this report on development of a method for analysis of Prasugrel will be helpful for drug-flavonoid interactions and Cytochrome induction & inhibition, phenotyping studies around the world by saving them from unnecessarily performing similar studies.
Effect of Morin on Pharmacokinetics of Prasugrel

Acknowledgments
The authors are thankful to Vice Chancellor, Jamia Hamdard, New Delhi for his constant encouragement and support. We also acknowledge Department of Science & Technology (DST) for providing research fellowship to Dr. Kapendra Sahu.

Conflict of Interest
The authors declare that they have no conflict of interest.

References